JP7696006B2 - 化膿性汗腺炎の治療における使用のためのレミブルチニブ - Google Patents

化膿性汗腺炎の治療における使用のためのレミブルチニブ Download PDF

Info

Publication number
JP7696006B2
JP7696006B2 JP2023553381A JP2023553381A JP7696006B2 JP 7696006 B2 JP7696006 B2 JP 7696006B2 JP 2023553381 A JP2023553381 A JP 2023553381A JP 2023553381 A JP2023553381 A JP 2023553381A JP 7696006 B2 JP7696006 B2 JP 7696006B2
Authority
JP
Japan
Prior art keywords
lou064
pharmaceutical composition
treatment
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023553381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511938A (ja
Inventor
バッタチャリヤ，ソヴィク
ビエス，ブルーノ
チェンニ，ブルーノ
グラハム，ゴードン
ユンケ，ミヒャエル
ロッシェ，クリスチャン
ラップ，カリン
シン，キム－ヒエン
ベンジャミン ツェラー，ジョナス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024511938A publication Critical patent/JP2024511938A/ja
Priority to JP2025095960A priority Critical patent/JP2025134747A/ja
Application granted granted Critical
Publication of JP7696006B2 publication Critical patent/JP7696006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023553381A 2022-02-28 2023-02-27 化膿性汗腺炎の治療における使用のためのレミブルチニブ Active JP7696006B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025095960A JP2025134747A (ja) 2022-02-28 2025-06-09 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US63/314,572 2022-02-28
US202263369016P 2022-07-21 2022-07-21
US63/369,016 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025095960A Division JP2025134747A (ja) 2022-02-28 2025-06-09 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Publications (2)

Publication Number Publication Date
JP2024511938A JP2024511938A (ja) 2024-03-18
JP7696006B2 true JP7696006B2 (ja) 2025-06-19

Family

ID=85570288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023553381A Active JP7696006B2 (ja) 2022-02-28 2023-02-27 化膿性汗腺炎の治療における使用のためのレミブルチニブ
JP2025095960A Pending JP2025134747A (ja) 2022-02-28 2025-06-09 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025095960A Pending JP2025134747A (ja) 2022-02-28 2025-06-09 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Country Status (11)

Country Link
US (1) US20250099465A1 (https=)
EP (1) EP4486346A1 (https=)
JP (2) JP7696006B2 (https=)
KR (1) KR20240155278A (https=)
CN (1) CN120617264A (https=)
AU (1) AU2023225222A1 (https=)
CA (1) CA3251002A1 (https=)
IL (1) IL314205A (https=)
MX (1) MX2024010392A (https=)
TW (1) TW202342048A (https=)
WO (1) WO2023161887A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234779A1 (en) 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CR20180285A (es) 2015-11-26 2018-07-16 Novartis Ag Derivados novedosos de diamino piridina
RU2749547C2 (ru) 2016-09-23 2021-06-15 Новартис Аг Индазольные соединения для применения при повреждениях сухожилий и/или связок
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3849559A4 (en) * 2018-09-12 2022-06-01 Denovo Biopharma LLC COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
AU2021205248A1 (en) * 2020-01-08 2022-09-01 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
MX2023008671A (es) 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234779A1 (en) 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clin Transl Sci.，2021年，Vol.14，p.1756-1768
JCI Insight，2020年，Vol.5, No.19, e139930，p.1-17

Also Published As

Publication number Publication date
MX2024010392A (es) 2024-09-06
WO2023161887A1 (en) 2023-08-31
TW202342048A (zh) 2023-11-01
EP4486346A1 (en) 2025-01-08
KR20240155278A (ko) 2024-10-28
CA3251002A1 (en) 2023-08-31
AU2023225222A1 (en) 2024-07-25
CN120617264A (zh) 2025-09-12
JP2024511938A (ja) 2024-03-18
JP2025134747A (ja) 2025-09-17
US20250099465A1 (en) 2025-03-27
IL314205A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US20240350477A1 (en) Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN117205312A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
US20250268876A1 (en) Treatment of hidradenitis suppurativa with orismilast
JP2020533381A (ja) トラジピタントによるアトピー性皮膚炎の改善された治療
KR20220012281A (ko) 브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법
JP2025134747A (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
JP2025508359A (ja) 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
Xiang et al. Tiamulin inhibits TNF-α and alleviates psoriasis-like dermatitis
AU2018209807B2 (en) Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy
JP7594124B2 (ja) Ｌｏｕ０６４を使用した治療の方法
US20260069578A1 (en) Treatment of neutrophilic dermatoses
EA051701B1 (ru) Ремибрутиниб для применения в лечении гнойного гидраденита
CN118742308A (zh) 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼
Williams et al. 294 Milk, Microbes, and Monoclonals: How Biologic Therapy Might Shape Maternal–Infant Microbiome Dynamics in Hidradenitis Suppurativa
Spellman et al. 290 Clinical Study of RLS-1496 Topical Cream: Targeting Cellular Senescence in Patients with Mild to Moderate Plaque Psoriasis, Atopic Dermatitis, and Aged Skin
Maya et al. 293 Associations Between Hidradenitis Suppurativa and Cutaneous Squamous Cell Carcinoma in Skin of Color
Hassan et al. 292 The Role of Biosimilars Targeting IL-17 and IL-23 Pathways in Psoriasis: Addressing Global Disparities in Psoriasis Care
Henry et al. 288 Photodamage or Dermatomyositis? A Case of an Erythematous Rash in a 59-Year-Old Patient
Adil et al. Isolated unilateral lichen sclerosus of the sole
EA051816B1 (ru) Способы лечения с применением lou064
El Rakaawi et al. THU0397 Efficacy of pamidronate in children with osteogenesis imperfecta: An open prospective study
EP3459534A1 (en) Method for treating or preventing radiotherapy induced breast fibrosis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250609

R150 Certificate of patent or registration of utility model

Ref document number: 7696006

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150